Rules for approving similar complex medicines would change, potentially speeding up access
This bill would change how similar versions of complex medicines, called biosimilars, get approved. It would remove the general requirement for certain detailed studies on how these drugs affect the body or compare to original medicines. If the government decides these extra studies are still needed, it would have to give drug companies a written reason much earlier in the process.
Today, clinical studies for similar complex medicines generally must include assessments of how the drug affects the immune system, how it works in the body, or how well it compares to original medicines. After this bill, these specific assessments would no longer be generally required. However, if the government decides these extra studies are still needed, it would have to provide a written justification to the drug company by the earliest date they can submit their application.
S 1414 · 119th Congress · April 10, 2025 · AI Summary by gemini-2.5-flash · 7/10
Sign in to see your representatives' phone numbers
18 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.